What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.”In the company’s words, NCT07597629 on ClinicalTrials.gov
- Tested for
- Advanced Breast Cancer, Advanced Solid Tumor
- Main trialPhase 2
- “This is an open-label, multicenter Phase II clinical study conducted in subjects with advanced breast cancer.”In the company’s words, NCT07597629 on ClinicalTrials.gov
Other drugs for Advanced Breast Cancer
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up1
- 30 Nov 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Nov 2027 | A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer | |
| Phase 1Recruiting | 31 Oct 2026 | A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026